Egawa Naohiro, Takase Hajime, Josephine Lok, Takahashi Ryosuke, Arai Ken
Department of Radiology and Neurology, Neuroprotection Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Brain Circ. 2016 Jul-Sep;2(3):121-125. doi: 10.4103/2394-8108.192515. Epub 2016 Oct 18.
Oligodendrocyte precursor cells (OPCs), which give rise to mature oligodendrocytes (OLs), play important roles in maintaining white matter function. Even during the adulthood period, OPCs comprise roughly 5% of all cells in the forebrain and retain a capability to become myelinated OLs. Recently, OPCs have been proposed as a novel source for cell-based therapy. For the purpose, OPCs can be obtained from embryonic stem cells, induced pluripotent stem cells, and directly converted cells derived from patients. Here, we will provide a brief review of the potential of using OPCs as a cell-based therapy for treating various neurological diseases.
少突胶质前体细胞(OPC)可分化为成熟的少突胶质细胞(OL),在维持白质功能方面发挥着重要作用。即使在成年期,OPC在前脑所有细胞中约占5%,并保留着分化为有髓鞘OL的能力。最近,OPC已被提议作为细胞疗法的一种新来源。为此,OPC可从胚胎干细胞、诱导多能干细胞以及直接重编程的患者来源细胞中获取。在此,我们将简要综述将OPC用作细胞疗法治疗各种神经疾病的潜力。